# Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

> **NCT06169371** · PHASE4 · RECRUITING · sponsor: **University of Illinois at Chicago** · enrollment: 50 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Abemaciclib
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT06169371
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-28
- **Primary completion:** 2030-11
- **Final completion:** 2030-11
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06169371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06169371, "Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06169371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*